Estimate of Economic Impact of Immune Checkpoint Inhibitors for NSCLC Relative to PD-L1 Expression in the US

被引：1
|
作者：
Aguiar, Pedro, Jr. [1 ]
De Mello, Ramon [2 ]
Tadokoro, Hakaru [1 ]
Babiker, Hani [3 ]
Gutierres, Barbara [4 ]
Lopes, Gilberto [5 ]
机构：
[1] Univ Fed Sao Paulo, Sao Paulo, Brazil
[2] Univ Algarve, Faro, Portugal
[3] Honor Hlth, Scottsdale, AZ USA
[4] Univ Paulista, Sao Paulo, Brazil
[5] Ctr Paulista, Oncol & Oncoclin Grp, Sao Paulo, Brazil
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
biomarker; Immunotherapy; Cost of Care; Access;
D O I：
10.1016/j.jtho.2016.11.324
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA17.01
引用
收藏
页码：S308 / S308
页数：1
相关论文
共 50 条
  • [1] Cost effectiveness and estimate of economical impact of immune checkpoint inhibitors for NSCLC relative to PD-L1 expression
    Aguiar Junior, P. N.
    De Mello, R.
    Tadokoro, H.
    Babiker, H. M.
    Lopes, G., Jr.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] An Estimate of the Economic Impact of Treatment of NSCLC With Immunotherapy Relative to PD-L1 Expression in Brazil
    Aguiar, Pedro, Jr.
    De Mello, Ramon
    Tadokoro, Hakaru
    Gutierres, Barbara
    Barreto, Carmelia
    Babiker, Hani
    Lopes, Gilberto
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S246 - S246
  • [3] Cost effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression.
    Aguiar, Pedro Nazareth
    Tadokoro, Hakaru
    Barreto, Carmelia Maria Noia
    Santoro, Ilka Lopes
    De Mello, Ramon Andrade
    Babiker, Hani M.
    Avancha, Kiran
    Lopes, Gilberto
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Cost-effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression
    Aguiar, Pedro, Jr.
    Perry, Luke A.
    Lopes, Gilberto L., Jr.
    LUNG CANCER MANAGEMENT, 2016, 5 (03) : 119 - 122
  • [5] Efficacy of PD-1/PD-L1 Immune Checkpoint Inhibitors for Advanced NSCLC According to PD-L1 Expression: A Meta-Analysis
    Ma, K.
    Guo, Y.
    Wang, Y.
    Wang, X.
    Xu, Y.
    Sun, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S584 - S584
  • [6] An Estimate of the Economic Impact of Immunotherapy Relative to PD-L1 Expression in Brazil - An Update with Brazilian Costs
    Aguiar, Pedro, Jr.
    De Mello, Ramon
    Tadokoro, Hakaru
    Babiker, Hani
    Lopes, Gilberto
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S427 - S427
  • [7] The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC
    Aguiar, P. N., Jr.
    Perry, L. A.
    Penny-Dimri, J.
    Babiker, H.
    Tadokoro, H.
    de Mello, R. A.
    Lopes, G. L., Jr.
    ANNALS OF ONCOLOGY, 2017, 28 (09) : 2256 - 2263
  • [8] Efficacy of Immune-Checkpoint Inhibitors and EGFR-TKIs in NSCLC Patients with High PD-L1 Expression
    Masuda, K.
    Horinouchi, H.
    Tanaka, M.
    Higashiyama, R.
    Shinno, Y.
    Sato, J.
    Yoshida, T.
    Matsumoto, Y.
    Goto, Y.
    Kanda, S.
    Yamamoto, N.
    Ohe, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S292 - S293
  • [9] Identifying Resistance to Immune Checkpoint Inhibitors by Screening for PD-L1 and MHC I Expression on CTCs in Pts with NSCLC
    Leal, T.
    Schehr, J.
    Kamisnki, A.
    Campbell, T.
    Traynor, A.
    Lang, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S924 - S925
  • [10] Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors
    Castello, A.
    Rossi, S.
    Toschi, L.
    Lopci, E.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S66 - S67
12345